Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
2.240
-0.020 (-0.88%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ZyVersa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
December 07, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why ZyVersa Therapeutics Shares Are Down 40%
December 07, 2023
ZyVersa Therapeutics Inc (NASDAQ: ZVSA) shares are trading lower by 43.7% to $1.20 Thursday morning.
Via
Benzinga
Nasdaq Jumps Over 100 Points; US Jobless Claims Edge Higher
December 07, 2023
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 36,068.53 while the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rivian (RIVN) Stock Just Scored a New ‘Buy’ Rating
December 07, 2023
Rivian stock is gaining on Thursday after Stifel weighed in on RIVN shares with a buy rating and set a price target of $25 per share.
Via
InvestorPlace
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today?
December 07, 2023
ZyVersa Therapeutics stock is falling hard on Thursday after the company priced a public offering for shares of ZVSA this morning.
Via
InvestorPlace
Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
December 07, 2023
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) jumped in pre-market trading after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of approximately...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
December 07, 2023
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
Via
InvestorPlace
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
December 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Shopify (SHOP) Stock Falls Following Analyst Downgrade
December 06, 2023
Shopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt.
Via
InvestorPlace
Why Is Pharvaris (PHVS) Stock Up 36% Today?
December 06, 2023
Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants.
Via
InvestorPlace
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today?
December 06, 2023
ZyVersa Therapeutics stock is rising with heavy trading of ZVSA shares after a paper was published in a peer-reviewed journal.
Via
InvestorPlace
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
December 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 30, 2023
Via
Benzinga
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
November 30, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
November 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 14, 2023
Via
Benzinga
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 13, 2023
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 13, 2023
Via
Benzinga
US Stocks Fall; Tyson Foods Posts Upbeat Earnings
November 13, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.08% to 34,254.53 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 13, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 13, 2023
Pre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 09, 2023
Via
Benzinga
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
November 09, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
November 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 01, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 01, 2023
Via
Benzinga
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing
November 01, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
October 25, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
October 18, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
October 11, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.